Meet an Unreasonable Venture
EpiBone
Creating bone tissue from a patient's mesenchymal stem cells in vitro for use in bone grafts.
Notable Achievements
- IND approval by the FDA in July 2023 to go into Ph 1/2 clinical trials with our cartilage product.
- Successful completion of our Ph 1/2 clinical trial of our bone product in August 2023.
- $45.8M of equity funding and $3M in grant funding raised to date.
Currently Operating in Six Regions
Press Mentions
July 24, 2023
EpiBone to Start Clinical Trials for Knee Cartilage Grown in Lab
/PRNewswire/ -- EpiBone has received Investigational New Drug (IND) clearance from the FDA to begin testing its lab-grown knee cartilage in humans. The...
Read on PRNewswire »
October 25, 2023
Behind Nina Tandon — The Big Apple and the Biotech Founder
Nina Tandon, a biotech entrepreneur, shares her journey from growing up in New York City to founding her own company. She discusses the challenges she faced and the importance of diversity in the...
Read on Brown Girl Magazine »
March 9, 2023
EpiBone, emerging biotech company, is relocating to Jersey City — and bringing nearly 100 jobs | ROI-NJ
EpiBone, an emerging biotechnology company co-founded and run by Nina Marie Tandon, is coming to Jersey City after the Board of the New Jersey Economic Development Authority (NJEDA) approved up to...
Read on ROI-NJ »
October 17, 2015
Why Peter Thiel Invested In New York Biotech Startup EpiBone
EpiBone uses stem cells to regrow damaged bones. After getting a PhD from Columbia, Nina Tandon returned to school for an MBA to form a company at the forefront of 'biology as design.'
Read on Inc.com »More Ventures in Health
Get the Unreasonable Newsletter
Get monthly updates on EpiBone and over 384 other ventures working to solve the world's toughest problems.